Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society [Yahoo! Finance]
Artelo Biosciences, Inc. (ARTL)
US:NASDAQ Investor Relations:
artelobio.com/investors
Company Research
Source: Yahoo! Finance
SOLANA BEACH, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that Professor Saoirse O'Sullivan will be presenting new preclinical data on ART26.12 at the th Annual Scientific Meeting of the British Pain Society . The conference is being held from June 4-6, 2024, in Nottingham, UK. The presentations, titled, “ ART26.12, a Novel Fatty Acid-binding Protein 5 Inhibitor, shows Efficacy in Breast Cancer-Induced Bone Pain ” and “ The Effects of the Fatty Acid Binding Protein 5 Inhibitor ART26.12 in a Rat Model of Diabetic Neuropathy ,” highlight Artelo's Fatty Acid Binding Protein 5 (FABP5) inhibitor under development for painful peripheral neuropathies and various cancers. Specifically, effective doses and plasma exposures are consistent with previously
Show less
Read more
Impact Snapshot
Event Time:
ARTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTL alerts
High impacting Artelo Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ARTL
News
- Artelo Biosciences, Inc. (NASDAQ: ARTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain SocietyGlobeNewswire
- Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24 [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24GlobeNewswire
- Artelo Biosciences, Inc. (NASDAQ: ARTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
ARTL
Sec Filings
- 6/17/24 - Form 25-NSE
- 5/13/24 - Form 10-Q
- 3/29/24 - Form S-8
- ARTL's page on the SEC website